Womens Health Investment Outlook 2026
Page 38 of 47 · WEF_Womens_Health_Investment_Outlook_2026.pdf
Appendix B:
Additional figures
Funding events (number) at the intersection of therapeutic and industry areas (2020–2025) FIGURE 15
1,203 Women’s cancers
906 Reproductive health
572 Maternal health
280 Generic women’s health
156 Mental health
82 Endometriosis
39 PCOS
24 Infectious diseases
15 Endocrine disorders
12 Urological disorders
11 Cardiovascular disorders
11 Menstrual health
8 Metabolic disorders
6 Menopausal health
4 Neurological disorders
3 MSK and pain disorders
Biopharma
and
therapeuticsCare delivery
and health
servicesDiagnostics Digital
health and
platformsConsumer
health and
wellnessMedtech
and devicesOther16 354 363 486 532 579 1002 3332 Grand totalTherapeutic areas (number of events)
Industry areas (number of events)
Funding events: <50 50–<100 100–<500 500+
Note: PCOS = polycystic ovary syndrome; MSK = musculoskeletal.
Source: Pitchbook, CapIQ, Crunchbase, Boston Consulting Group
Women’s Health Investment Outlook
38
Ask AI what this page says about a topic: